Business Wire

Theramex launches Bijuva ® / Bijuve ® (estradiol and progesterone) , the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Share

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE

FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY

Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3

Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have not been shown to increase the risk of venous thromboembolism and are safer forms of HRT with respect to the risk for breast cancer, heart disease, heart attack, and stroke.6-8

The idea of using body identical hormones to replace estrogens and to protect the endometrium with progesterone appeals to many women9.These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.1,9

Dr Paula Briggs, incoming Chair of the British Menopause Society, said, “We know women can be concerned about taking hormones and the impact they may have on their health beyond treating menopause symptoms. The availability of a body-identical progesterone which is well tolerated and has a lower risk profile than oral synthetic progestogens, combined with estradiol in a single capsule, is great news for women. As a healthcare community we should encourage our patients to reconsider the benefits of newer therapeutic options, allowing them to make informed choices.”

Theramex CEO, Robert Stewart, commented,For many years menopausal women and their healthcare providers have been seeking an EMA approved body-identical combination therapy. The approval of Bijuva® / Bijuve® during Menopause Awareness month represents an important new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms.”

ENDS

Notes to Editor

About Bijuva® / Bijuve®

Bijuva® / Bijuve®is a fixed dose, oral, continuous combined hormonal replacement therapy (HRT) capsule containing 1mg estradiol and 100mg micronised progesterone.1 Known as Bijuve® in the UK, it is the first approved oral continuous combined body-identical estradiol–progesterone formulation in a single capsule.2 It is indicated for continuous combined HRT for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.1 In a robust, long-term, phase III clinical trial, Bijuva® / Bijuve®demonstrated clinically relevant and statistically significant improvement in the reduction of frequency and severity of moderate-to-severe vasomotor symptoms (VMS) such as hot flushes and night sweats as early as week 3 vs placebo.9 It also demonstrated significant improvement in sleep without causing drowsiness, which delivered a significant improvement in quality of life for women taking part in the study.9 Importantly Bijuva® / Bijuve®safety was studied over 12 months of treatment, and demonstrated endometrial protection, as well as no significant changes in lipid, coagulation or glucose parameters as compared to placebo.9

The most common adverse reactions (≥3 percent) were breast tenderness, headache, vaginal bleeding, vaginal discharge and vaginal hemorrhage.9 Theramex has a license and supply agreement with TherapeuticsMD (Nasdaq: TXMD) to commercialize BIJUVA outside the United States, Canada and Israel.10

The burden of menopause

During menopause, patients may experience undesirable symptoms including vasomotor symptoms (VMS) such as hot flushes and night sweats. 11-15 In addition, women may also experience sleep deprivation, headaches, inability to concentrate, loss of memory, mood swings, vaginal dryness, loss of libido and stiffness of joints and muscles, all of which can deteriorate their quality of life. 11-15 It is estimated that vasomotor symptoms are experienced by around 75% of menopausal womenand for around a third of these women, symptoms are severe.5 Up to three-quarters of post-menopausal women experience sleep disorders, which negatively impact health-related quality of life (HRQoL) and work productivity.16,17 Menopausal symptoms can typically last around 4 years, and in around 10% of women can last up to 12 years post-menopause.4 Direct and indirect costs associated with caring for women with VMS are significantly higher than for women without VMS.16,18

About Theramex

Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

References

* With intact uterus and at least 12 months since last menses

1 Theramex 2021, Summary of Product Characteristics

2 FDA Summary Review. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000SumR.pdf. Accessed September 2021.

3 Kuhl H. 2005;8(Suppl 1):3-63.

4 National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/ng23/. Accessed September 2021.

5 British Menopause Society. Available at https://thebms.org.uk/publications/consensus- statements/hormone-replacement-therapy/. Accessed September 2021.

6 Holtorf K. Postgrad Med. 2009;121(1):73–85.

7 Mirkin S. Climateric. 2018;21(4):346-354.

8 Fournier A, Berrine F, Clavel-Chapelon F. Breast Cancer Res Treat. 2008;107:103-111.

9 Archer DF, Bernick BA, Mirkin S. Expert Rev Clin Pharmacol. 2019;12(8):729–39.

10 Theramex. (7th June 2019). https://www.sec.gov/Archives/edgar/data/25743/000138713119004260/ex99-1.htm

11 Davis SR et al. Nat Rev Dis Primers. 2015;1: 15054. Menopause. Nat Rev 2015;1:1-19

12 Greendale GA et al. JAMA. 2020;323(15):1495-6.

13 Joffe Het al. Clin Endocrinol Metab. 2016; 101(10): 3847-55.

14 Zervas IM et al. Menopause. 2009;16(4): 837-42.

15 Jehan S et al. J Sleep Disord Ther. 2015;4(5):1-18.

16 DiBonaventura MD et al. Int J Womens Health. 2013;5:261–9.

17 Baker FC et al. Sleep Med Clin. 2018;13(3):443–56.

18 Sarrel P et al. Menopause. 2015;22(3):260–6.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Bradley, Head of Communications Theramex
andrew.bradley@theramex.com / +44 (0)7864 167 962

Claire Paling, Makara Health
helenrae@makarahealth.com / +44(0)7594 225 273

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PAN Finance Names Libertex ‘Global CFD Broker of the Year’29.3.2024 06:25:00 CET | Press release

As the first quarter of 2024 draws to a close, Libertex is thrilled to announce its first accolade of the new year! The established global financial publication PAN Finance has determined Libertex to be the ‘CFD Broker of the Year – Global 2024’ following a rigorous evaluation process conducted by the publication's highly experienced editorial and research teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328235325/en/ (Graphic: Libertex) PAN Finance is a trusted source of global financial intelligence with an impressively wide readership across 150 countries. Its ecosystem includes a quarterly magazine, special reports, a news website, and various social media channels. As an organisation, PAN Finance is committed to providing concise, intelligent, and up-to-date news for a worldwide readership of specialists spanning the entire finance industry. The company's awards programme aims to serve as a true indicator of exc

Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.29.3.2024 02:39:00 CET | Press release

Midea Group: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328526418/en/ Background: Midea Group, a leading global technology group, recently released its 2023 Environmental, Social, and Governance (ESG) Report with ambitious sustainable development goals set for 2030. They include achieving over 500 megawatts of photovoltaic power generation, reducing greenhouse gas emission intensity (scopes 1 and 2) by 0.040, secure Energy Management System Certification for 50 factories, and achieve 100% carbon footprint accounting for major categories of smart home appliances. This is aligned with the Sustainable Development Report Standards of the Global Report Standards of the Global Reporting Initiative (GRI). The new report and campaign focuses on four dimensions: Protect the Blue Planet, Build a Harmonious Community, Practice 'Bring Great Innovations to Life', and Jointly Create the Prosperous Ecology. The campaign: Midea’s ESG

DC Secretary Announces Annual Determinations Committees Outcome28.3.2024 21:14:00 CET | Press release

DC Administration Services, Inc. has today announced the composition of five regional Determinations Committees (DCs), effective from April 27, 2024. Voting Dealers (for all regions): Voting Non-Dealers (for all regions): Bank of America N.A. Citadel LLC Barclays Bank plc Elliott Management Corporation BNP Paribas Pacific Investment Management Company LLC Citibank, N.A. Deutsche Bank AG Goldman Sachs International JPMorgan Chase Bank, N.A. Voting Dealer for the Americas, EMEA, AEJ, and Japan Determination Committees: Mizuho Securities Co., Ltd. The process for selecting DC members is specified in the DC rules. The DC rules, along with more information about the Determinations Committees and what they do can be found at the Determinations Committees website: https://www.cdsdeterminationscommittees.org/. View source version on businesswire.com: https://www.businesswire.com/news/home/20240328441002/en/Contact information Press Inquiries: Orlando Figueroa orlando.figueroa@citadelspv.com

Faster Recoveries, Improved Security: HTEC and G2 Risk Solutions Join Forces to Advance Bankruptcy Management28.3.2024 17:02:00 CET | Press release

HTEC, a global digital consulting, software engineering, and product development company, is announcing a strategic collaboration with G2 Risk Solutions (G2RS), the preeminent provider of end-to-end bankruptcy technology solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328622816/en/ HTEC & G2 Risk Solutions Partnership (Photo: Business Wire) Under the agreement, G2RS will engage HTEC to incorporate its leading-edge technology into G2RS’ premier bankruptcy management platform. As the creators of the most comprehensive national bankruptcy database and the first bankruptcy management portal, G2RS is an industry pioneer. By adding HTEC’s premium engineering to the G2RS technology stack, G2RS will offer new and innovative functionalities to help clients expedite financial recoveries, increase data protection, and reduce operational inefficiencies in the bankruptcy management life cycle. “We are thrilled to be a part o

The reopening of the Yokohama Museum of Art adds another innovative and distinctive venue for events in Yokohama28.3.2024 16:00:00 CET | Press release

After extensive renovations, the iconic Yokohama Museum of Art has reopened its doors to visitors from all over the world. The museum’s reopening paves the way to new and closer collaboration with international events in Yokohama. This extraordinary venue is the ideal setting for a one-of-a-kind gathering, in part, supported by the Yokohama Convention & Visitors Bureau (hereinafter YCVB). The Yokohama Museum of Art Founded in 1989, the Yokohama Museum of Art collects over 14,000 works of art that reflect the many facets of life in Yokohama—past, present, and future. The reopening of the museum coincides with the Yokohama Triennale, an international exhibition featuring contemporary artists whose decentralized exhibits turn the entire metropolis into an art museum. The 8th Yokohama Triennale is being held from March 15 to June 9, 2024, with the Yokohama Museum of Art being a pivotal venue for the exhibition. With the museum firmly back on the map as Yokohama’s leading artistic venue, YC

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye